Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Vitamin E in the prevention of cardiovascular disease: the importance of proper patient selection.

Vardi M, Levy NS, Levy AP.

J Lipid Res. 2013 Sep;54(9):2307-14. doi: 10.1194/jlr.R026641. Epub 2013 Mar 15. Review.

2.
3.

Antioxidants in the prevention of atherosclerosis: the importance of proper patient selection.

Levy Y, Blum S, Levy AP.

Clin Nutr. 2009 Oct;28(5):581-2. doi: 10.1016/j.clnu.2009.04.012. Epub 2009 May 22.

PMID:
19464773
4.

Pharmacogenomic application of the haptoglobin genotype in the prevention of diabetic cardiovascular disease.

Blum S, Milman U, Shapira C, Levy AP.

Pharmacogenomics. 2008 Aug;9(8):989-91. doi: 10.2217/14622416.9.8.989. No abstract available.

5.
6.

Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype.

Blum S, Vardi M, Brown JB, Russell A, Milman U, Shapira C, Levy NS, Miller-Lotan R, Asleh R, Levy AP.

Pharmacogenomics. 2010 May;11(5):675-84. doi: 10.2217/pgs.10.17.

7.

Patient selection and vitamin E treatment in diabetes mellitus.

Goldenstein H, Levy NS, Lipener YT, Levy AP.

Expert Rev Cardiovasc Ther. 2013 Mar;11(3):319-26. doi: 10.1586/erc.12.187. Review.

9.

Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy.

Lonn E, Yusuf S, Hoogwerf B, Pogue J, Yi Q, Zinman B, Bosch J, Dagenais G, Mann JF, Gerstein HC; HOPE Study; MICRO-HOPE Study.

Diabetes Care. 2002 Nov;25(11):1919-27.

PMID:
12401733
10.

Vitamin E and heart disease: basic science to clinical intervention trials.

Pryor WA.

Free Radic Biol Med. 2000 Jan 1;28(1):141-64. Review.

PMID:
10656300
11.

Haptoglobin: a major susceptibility gene for diabetic cardiovascular disease.

Levy AP.

Isr Med Assoc J. 2004 May;6(5):308-10. Review. No abstract available.

12.

The antioxidant vitamins and cardiovascular disease. A critical review of epidemiologic and clinical trial data.

Jha P, Flather M, Lonn E, Farkouh M, Yusuf S.

Ann Intern Med. 1995 Dec 1;123(11):860-72. Review.

PMID:
7486470
13.

Does vitamin E supplementation prevent cardiovascular events?

Manson JE, Bassuk SS, Stampfer MJ.

J Womens Health (Larchmt). 2003 Mar;12(2):123-36. Review.

PMID:
12741415
14.
15.
16.

The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes.

Blum S, Vardi M, Levy NS, Miller-Lotan R, Levy AP.

Atherosclerosis. 2010 Jul;211(1):25-7. doi: 10.1016/j.atherosclerosis.2010.02.018. Epub 2010 Feb 21. No abstract available.

17.

Haptoglobin genotype and its role in diabetic cardiovascular disease.

Costacou T, Levy AP.

J Cardiovasc Transl Res. 2012 Aug;5(4):423-35. doi: 10.1007/s12265-012-9361-z. Epub 2012 Mar 24. Review.

18.

The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes.

Levy AP, Gerstein HC, Miller-Lotan R, Ratner R, McQueen M, Lonn E, Pogue J.

Diabetes Care. 2004 Nov;27(11):2767. No abstract available.

PMID:
15505023
19.

Vitamin E and cardiovascular disease: observational studies.

Gaziano JM.

Ann N Y Acad Sci. 2004 Dec;1031:280-91. Review.

PMID:
15753154
20.

Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials.

Myung SK, Ju W, Cho B, Oh SW, Park SM, Koo BK, Park BJ; Korean Meta-Analysis Study Group.

BMJ. 2013 Jan 18;346:f10. doi: 10.1136/bmj.f10. Review.

Supplemental Content

Support Center